Please assess the completion status of the following clinical trial:

Trial Title: The Preterm Infants' Paracetamol Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* preterm infants born \< 32 weeks gestational age~Exclusion Criteria:~* congenital malformation~* lethal disease~* chromosomal abnormality~* persistent pulmonary hypertension of a newborn

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- Paracetamol effect on ductus (Type: EXPERIMENTAL): The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.
- Paracetamol effect on pain (Type: EXPERIMENTAL): The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).